BIOMARIN PHAR. DL-,001 | 67.07 / -0.43% |
Date/Time | 01/15 / 08:07 |
Chg. / Chg.(%) | -0.29 / -0.43% |
Bid | - |
Ask | - |
Open | 67.07 |
Previous Close | 67.36 |
High | 67.07 |
Low | 67.07 |
Volume [EUR] | 0.00 |
Volume [Units] | 0 |
Price fixings | 1 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | München |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 82.9700 | ![]() |
1,277,910 |
Cboe US | 82.85 | ![]() |
89,323 |
IEX | 82.89 | ![]() |
62,135 |
TradeGate | 68.200 | ![]() |
988 |
Vienna Globa.. | 68.08 | ![]() |
849 |
gettex | 69.110 | ![]() |
70 |
Frankfurt | 67.7500 | ![]() |
64 |
Xetra | 68.08 | ![]() |
0 |
Berlin | 66.75 | ![]() |
0 |
München | 67.07 | ![]() |
0 |
Düsseldorf | 68.45 | ![]() |
0 |
Stuttgart | 68.800 | ![]() |
0 |
Lang & Schwa.. | 67.03 | ![]() |
|
Mexico | 1,599.31 | ![]() |
4,200 |
London Inter.. | 81.84 | 295 |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire